Coagulopathy, injury severity and bleeding progression but not prior antiplatelet and anticoagulation therapies drive prognosis in patients with moderate to severe traumatic brain injury.

ABSTRACT:

Introduction

Antiplatelet and anticoagulant therapies complicate the management and outcomes of traumatic brain injury (TBI) patients. This study evaluates clinical profiles and short-term outcomes focusing on prior antihemostatic therapy and tranexamic acid (TXA) use.

Patients and methods

We analyzed TBI patients admitted to University Hospital Frankfurt (2018-2021), assessing demographics, injury characteristics, clinical course, and short-term outcomes. The primary endpoint was hemorrhage progression; secondary endpoints included the modified Rankin Scale (mRS) at discharge, mortality and thromboembolic complications. Regression models identified predictors of functional outcome and mortality.

Results

Among 218 patients (median age 70 years, 35% female, median GCS

SUBMITTER: Lieschke F 

PROVIDER: S-EPMC12283275 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature